Generics producer Par Pharmaceuticals (NYSE: PRX) has been snapped up by a global private equity firm TPG in a deal that values the company at $1.9 billion, the tenth largest deal for the year to date, according to data from Dealogic. Par may well try to get a better deal since it’s got until August […]
Par Pharmaceuticals (NYSE: PRX) completed its third generics deal in six months with the $20.5 million acquisition of a drug developer and manufacturer based in India. Edict Pharmaceuticals has 11 abbreviated new drug applications filed with the U.S. Food and Drug Administration. In November, Par Pharmaceuticals completed its $410 million deal to acquire Anchen Pharmaceuticals, […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Par Pharmaceuticals (NYSE: PRX) revved up its generic drugs category with two substantial acquisitions in the third quarter as several companies seek to benefit from the imminent expiration of exclusive patents. In August, the Woodcliff Lakes, New Jersey drug company agreed to acquire Anchen Pharmaceuticals, a privately-held company focused on developing and commercializing extended release […]
Generic competition to Pozen’s (NASDAQ:POZN) migraine drug Treximet will be held at bay for now. A judge in the U.S. District Court for the Eastern District of Texas has granted a preliminary injunction that orders Par Pharmaceutical (NYSE:PRX) not to make or sell a generic version of Treximet, which is sold in the United States […]
Looming patent expiration on the migraine drug Treximet has led pharmaceutical company Pozen to take further legal action to fend off generic competition. Chapel Hill, North Carolina-based Pozen (NASDAQ:POZN) said Tuesday it has filed a preliminary injunction to prevent Par Pharmaceuticals from launching a Treximet generic. Pozen made the filing in the U.S. District Court […]